Krishna Institute of Medical Sciences Limited has scheduled one-on-one meetings with analysts and institutional investors on June 04, 2026. The interactions will be conducted via calls, video conference, or in-person sessions to discuss the general business outlook and information already available in the public domain.

The company confirmed that no unpublished price sensitive information (UPSI) will be disclosed during these meetings. This intimation was made pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Nagajayanthi J. R, Company Secretary and Compliance Officer, signed the disclosure on behalf of the company. The schedule remains subject to change due to exigencies on the part of the investors or the company.

Krishna Institute of Medical Sciences announced its audited consolidated financial results for the quarter and financial year ended March 31, 2026. The company reported a 28.2% year-on-year increase in total revenue to INR 3,931 Cr for FY26, compared to INR 3,067 Cr in the previous year. Despite robust top-line growth, profitability declined with PAT falling to INR 242 Cr from INR 415 Cr in FY25. The board approved these results on May 15, 2026.

FY26 Financial Performance

The company achieved an EBITDA of INR 828 Cr, a marginal increase of 1.6% YoY, while the EBITDA margin contracted to 21.1% from 26.6% in FY25. This margin compression reflects the impact of the company's aggressive expansion strategy and the ramp-up phase of newer facilities. The consolidated EPS for FY26 stood at INR 6.03, a degrowth of 37.2% on a YoY basis. The following table summarises the full-year consolidated financial performance:

Q4 FY26 Financial Highlights

For the fourth quarter of FY26, total revenue stood at INR 1,084.30 Cr, reflecting growth of 35.3% on a YoY basis and 8.1% on a QoQ basis. Revenue from operations grew 34.8% YoY and 7.7% QoQ to INR 1,074.60 Cr. Q4 EBITDA (including other income) came in at INR 216.20 Cr versus INR 202.50 Cr in Q4 FY25, a growth of 6.8% YoY and 5.9% QoQ. The EBITDA margin contracted to 19.9% from 25.3% in Q4 FY25 and 20.4% in Q3 FY26. Consolidated EBITDA Pre-INDAS and excluding other income stood at INR 187.00 Cr, a degrowth of 2.7% YoY and 0.6% QoQ. Q4 PAT was recorded at INR 33 Cr, compared to INR 106 Cr in Q4 FY25 and INR 52 Cr in Q3 FY26. Cash and cash equivalents stood at INR 90 Cr as on March 31, 2026.

Operational Highlights

Operational metrics showed strong volume growth during the fiscal year. Inpatient (IP) volume increased by 15.4% to 2,46,297, while Outpatient (OP) volume surged by 25.4% to 23,00,360. Average Revenue Per Occupied Bed (ARPOB) rose by 14.0% to INR 44,644, and Average Revenue Per Patient (ARPP) grew by 11.4% to INR 1,59,575. In Q4 FY26, ARPOB grew 13.7% YoY and 1.7% QoQ, while ARPP grew 14.0% YoY and 3.5% QoQ, indicating continued improvement in per-patient realisations.

Strategic Expansion and Management Commentary

KIMS Hospitals currently operates 26 hospitals with over 7,300 beds across Telangana, Andhra Pradesh, Karnataka, Kerala, and Maharashtra. The group plans to add more than 1,300 beds through upcoming projects, targeting a total bed capacity of 8,600+. During the earnings conference call held on May 18, 2026, management provided further insights into the performance. The company noted that mature units maintained a healthy EBITDA margin of approximately 29.5%, while newer units (operational for less than a year) caused an EBITDA erosion of INR 128 Cr for the full year. In Q4 FY26, newer units contributed INR 224 Cr to revenue, with an EBITDA erosion of INR 32 Cr.

The company plans to use proceeds from a planned Qualified Institutional Placement (QIP) to retire debt, estimated at INR 1,000 Cr, and fund greenfield projects. Management expects the EBITDA erosion from new units to reduce by more than half in the coming year as these facilities mature and insurance empanelments are completed. Commenting on the results, Dr. B. Bhaskara Rao, CMD, KIMS Hospitals, stated: "FY26 has been a year of accomplishments for us. Four new units across Bengaluru, Kerala and Thane have shown progress in the limited time of their operations."

Board Decisions and Corporate Developments

At the board meeting held on May 15, 2026, several significant corporate governance decisions were taken. The board appointed M/s. Sagar & Associates, Cost Accountants, as Cost Auditors for FY 2026-27, subject to member approval at the ensuing Annual General Meeting. Three personnel were identified as Senior Management Personnel (SMP) with immediate effect. Additionally, the board approved the re-designation of Mr. Adwik Bollineni from Non-Executive Director to Executive Director of the company, effective May 15, 2026. The company's 24th Annual General Meeting is scheduled for Thursday, August 27, 2026. The audited financial results received an unmodified opinion from statutory auditors S.R. Batliboi & Associates LLP.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE967H01025/0aada293d1814f00.pdf